Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer

Jin Young KimYoung Rok DoKeon Uk ParkJong Gwang KimYee Soo ChaeMin Kyoung KimKyung Hee LeeHun Mo RyooSung Hwa BaeJin Ho BaekHong Suk Song
Dept. of Internal Medicine (내과학)
Issue Date
Cancer Chemotherapy and Pharmacology, Vol.67(3) : 527-532, 2011
Objective : The present study was conducted to evaluate the efficacy and safety of a combination regimen of S-1, paclitaxel plus cisplatin in patients with advanced gastric cancer. Methods : Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxel 80 mg/m2 plus cisplatin 30 mg/m2 on days 1, 8 and S-1 35 mg/m2 orally twice daily on days 1–14 based on a 3-week cycle. Results : Forty-four patients were enrolled in the current study, among whom 38 were assessable for efficacy and all assessable for toxicity. Two complete response and 24 partial responses were confirmed, giving an overall response rate of 59.1%. At a median follow-up of 11.4 months, the median time to progression and median overall survival was 9.4 (95% CI 6.8–12.1) months and 11.2 (95% CI 7.6–14.8) months, respectively. Grade 3/4 neutropenia occurred in 45 events (20.9%) and febrile neutropenia was observed in five events (2.3%). The common non-hematologic toxicity was nausea (grade 1/2, 27.2%) and diarrhea (grade 1/2, 9.0%). Conclusion : The combination of S-1, paclitaxel and cisplatin was found to be well tolerated and effective in patients with advanced gastric cancer. Keywords : S-1 – Paclitaxel – Cisplatin – Chemotherapy – Gastric cancer
Appears in Collections:
1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Keimyung Author(s)
김진영; 도영록; 박건욱; 송홍석
Full Text
File in this Item
 사서에게 요청하기
RIS (EndNote)
XLS (Excel)


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.